The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 study of SGN-ALPV, a novel, investigational vedotin antibody–drug conjugate directed to ALPP/ALPPL2 in advanced solid tumors (SGNALPV-001, trial in progress).
 
Nehal J. Lakhani
Consulting or Advisory Role - Ikena Oncology; Innovent Biologics; SK Life Sciences
Research Funding - Alexion Pharmaceuticals; Alexo Therapeutics; Alpine Immune Sciences; Alpine Immune Sciences; Apexian Pharmaceuticals; Asana Biosciences; Ascentage Pharma; Astellas Pharma; BeiGene; Celgene; Cerulean Pharma; Constellation Pharmaceuticals; Coordination Therapeutics; CytomX Therapeutics; Epizyme; Formation Biologics; Forty Seven; Genmab; Gilead Sciences; GlaxoSmithKline; Helsinn Healthcare; Ikena Oncology; Incyte; InhibRx; Innovent Biologics; Jounce Therapeutics; LAM Therapeutics; Lilly; Livzon; Loxo; MacroGenics; Merck; Mersana; Northern Biologics; Odonate Therapeutics; Pfizer; Regeneron; Sapience Therapeutics; Seagen; Servier; Shattuck Labs; Symphogen; TaiRx, Inc.; Tesaro; Tizona Therapeutics, Inc.
 
Claire Frances Friedman
Honoraria - Aptitude Health; OncLive/MJH Life Sciences
Consulting or Advisory Role - Arch Oncology; Bristol Myers Squibb; Seagen
Research Funding - Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); Genentech (Inst); Merck (Inst)
(OPTIONAL) Uncompensated Relationships - Genentech; Merck
 
Cesar Augusto Perez
Consulting or Advisory Role - Regeneron
Research Funding - Alkermes (Inst); Artios (Inst); Kinnate Biopharma (Inst); Kura Oncology (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Ribon Therapeutics (Inst)
 
Alison Wehr
Employment - Seagen
Stock and Other Ownership Interests - Seagen
Travel, Accommodations, Expenses - Seagen
 
Suzanne M. McGoldrick
Employment - Seagen
Stock and Other Ownership Interests - Seagen
Consulting or Advisory Role - Abbvie (I); Allergan (I); Bristol-Myers Squibb/Celgene (I)
Research Funding - Abbvie (I); Allakos (I); Janssen (I); Takeda (I)
Travel, Accommodations, Expenses - Seagen
 
Patricia LoRusso
Honoraria - Five Prime Therapeutics
Consulting or Advisory Role - Abbvie; ABL Bio; Agenus; Agios; Astellas Pharma; AstraZeneca; BAKX Therapeutics; Bayer; Black Diamond Therapeutics; Compass Therapeutics; Cybrexa Therapeutics; CytomX Therapeutics; EMD Serono; Five Prime Therapeutics; Genentech; Genmab; GlaxoSmithKline; Halozyme; I-Mab; ImCheck therapeutics; ImmunoMet; IQvia; Kineta; Kyowa Kirin International; Macrogenics; Mekanistic Therapeutics; Molecular Templates; Molecular Templates; Pfizer; QED Therapeutics; Relay Therapeutics; Roche/Genentech; Salarius Pharmaceuticals; Seagen; Shattuck Labs; Silverback Therapeutics; SK Life Sciences; Sotio; ST Cube; Stemline Therapeutics; Takeda; Trial to Reduce IDDM in the Genetically at Risk (TRIGR); TYME; Zentalis
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Genentech